10 years experiences and trusting networks between Japan and the global market
Proactive Business Development
Biospire identifies innovative technologies and high potential businesses from the global market to connect to global stakeholders including corporate (open innovation, CVC, R&D), investors and ecosystems.
Chemically synthesizable mycoplasma antigens for vaccine development
M Biotech has key patents related to the structure of glycolipid on mycoplasma membrane surfaces as well as its synthesis methodology. These technologies can be applied to highly sensitive diagnoses and vaccine development using the glycolipid-antigen to produce its antibody. M Biotech is en-route to global business expansion by collaborating with business and technical partners.
M Bio Technology
VR for healthcare approaches
FOVE uses a unique eye tracking VR system, and is now looking for healthcare application partners such as dementia (cognitive) research fields, e.g. self-check device development.
Indoor hypoallergenic spray for reduction of fine dust particles and PM2.5
Herb Guardian invented the novel technology to combat the hazardous fine particulate matters in the atmosphere. They are a spinout company from Chulalongkorn University in Thailand.
License-free big surgical data from Japanese hospitals
Surg storage is a spin out of the National Cancer Hospital in Japan and can now provide surgical videos and surgical-related data for commercial use such as the quality improvement of medical devices.
iPSC derived artificial immature blood cells
MiCAN develops iPS-derived myeloid (immature dendritic cells) to be applied for virus research (including dengue and COVID-19) as well as for drug safety applications.
Probiotics technology suppressing methane gas production in cows' stomach
JFR collaborates with academia to develop technologies to supress methane gas (CH4) generations from livestock animals using own probiotics know-hows.
iPSC derived corneal endothelial cellular therapy
Cellusion owns IP and technologies to develop and obtain iPS-derived corneal endothelial cells suitable for corneal transplantation. They aim to derive enough therapeutic cells to treat thousands of patients from a single batch.
Super high pure, pluripotentable and scalable MSC
PuREC is a spinout from Shimane University with patented technologies to produce purified MSC, or mesenchymal stem cells. PuREC's REC is coming from Rapidly Expanding Cells enabling the synthesis of 10^12 ordered pure cells within 12 weeks without requiring complicated methodologies such as gene-modification.
Japan to Global
Why don't you explore your investment and business acquisition targets to high-end Japanese startup companies?
Biospire selects and supports best-in-class Japanese startup companies looking for global communications, collaborations, business development and investments.
Biospire introduces suitable startups to international stakeholders through an integrated endorsement system.
Endorsement of selected Japanese startup companies
Japan is increasingly recognized a great place to invest, however we know that it is difficult to identify the most promising and valuable startups. Biospire’s experienced consultant team endorses hand-selected startup companies using our vast experience and databases.
Proactive global business development support
Japanese startups may be missing a large international market. Many early-stage startups have not established clear global strategies. Biospire's global business experts will guide you to deliver global marketing, partnering you with the best investors and the supply chain management.
Global to Japan
Japan is a great place to explore your businesses. Our business development experts are fully versed in Japanese business culture to bridge you and the best business partners.
Biospire links to local ecosystems, government, distributors, business development specialists including sole-reps, and of course high value end-users.